Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 04/28 05:35:06 pm
71.56 EUR   -1.38%
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol..
04/24 UCB FIRST THREE :  UCB with …
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
70.35(c) 70.93(c) 72.91(c) 73.71(c) 71.56(c) Last
780 733 402 564 401 540 292 225 298 256 Volume
-1.72% +0.82% +2.79% +1.10% -2.92% Change
More quotes
Financials (€)
Sales 2017 4 284 M
EBIT 2017 934 M
Net income 2017 597 M
Debt 2017 551 M
Yield 2017 1,68%
Sales 2018 4 538 M
EBIT 2018 1 102 M
Net income 2018 728 M
Finance 2018 23,5 M
Yield 2018 1,82%
P/E ratio 2017 21,46
P/E ratio 2018 17,71
EV / Sales2017 3,38x
EV / Sales2018 3,06x
Capitalization 13 919 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
08/02Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
04/24 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
04/20 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
04/19UCB SA : quaterly earnings release
04/10 UCB : U.S. Patent and Trademark Office confirms validity of patent …
04/10 UCB : Acquisition of own shares
04/07 UCB : Acquisition of own shares
04/04 UCB : and Q-State Biosciences Form Research Collaboration …
04/03 AMGEN : Ucb and amgen report new data at endo 2017 examining the option of a sec..
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on UCB 
04/07There is still some upside potential
More Strategies
Latest Tweets
04/26UCB, Inc. Selects Medidata Solutions, Inc. Clinical Cloud To Support Patient-.. 
04/24Briefing actions (24 avril) - UCB, KBC, Solvay, Galapagos, Ontex, Nyrstar, Va..
1
04/24UCB First Three Months Interim Report 2017: UCB with …  
04/17.@chelseaperetti took on the family drama last week at #UCB
4
04/11Check out @shawna on @Two_Beers_In recorded last night at the UCB in NY  
More tweets
Qtime:28
News from SeekingAlpha
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
02/24 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q4 2016 Results - Earnings Call ..
02/23 UCB S.A. reports FY results
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 75,6 €
Spread / Average Target 5,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB17.48%15 162
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results